查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677201

按產品、技術平台和最終用戶分類的無細胞 DNA 檢測市場 - 2025 年至 2030 年全球預測

Cell-Free DNA Testing Market by Offerings, Technology Platform, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年無細胞DNA檢測市值將達67億美元，2025年將以7.52%的複合年成長率成長至71.9億美元，到2030年將達到103.6億美元。

主要市場統計數據
基準年 2024 年 67億美元
預計 2025 年 71.9億美元
預測年份 2030 103.6億美元
複合年成長率（%） 7.52％

無細胞 DNA（cfDNA）檢測已迅速發展成為現代診斷領域的變革工具。該技術從血液和其他體液中提取微量遺傳訊息，不僅提供了一種重要的非侵入性檢測選擇，而且為更早、更準確地檢測各種健康狀況鋪平了道路。在當今的醫療保健領域，無需手術干預即可獲取關鍵遺傳資料的能力重新定義了診斷方法並推動了各種臨床工作流程的模式轉移。

近年來，cfDNA方法取得了重大進展，並被應用於腫瘤學、產前護理、移植監測和傳染病檢查等多個醫學領域。該技術的日益複雜化促使其從小眾應用轉變為主流診斷資產。高靈敏度平台和創新訊號檢測技術的整合不僅提高了這些測試的準確性，而且增強了醫療保健提供者和患者的信心。

本全面概述探討了 cfDNA 檢測如何從早期的希望發展到目前的成熟狀態，並研究了關鍵促進因素、市場細分和主要區域趨勢。這項深入研究的目的是向行業領導者和決策者提供他們所需的洞察力，以便在技術創新迅速和臨床期望不斷提高的環境中利用這項技術。

改變無細胞 DNA 檢測市場

在快速的技術創新和不斷變化的臨床需求的推動下，cfDNA 檢測領域正在轉變。在過去幾年中，分析技術和分析設計的重大創新重塑了市場格局。透過整合次世代定序、微流體和單分子甲基化分析，可以提高敏感性和特異性，從而改變臨床醫生進行早期診斷和個人化治療計劃的方式。

從歷史上看，侵入性切片檢查技術一直是臨床診斷的主要手段，但通常具有固有的風險和限制。轉向非侵入性cfDNA檢測不僅最大限度地降低了這些風險，而且還擴大了在疾病早期獲取關鍵診斷資訊的管道。這種演變在腫瘤學和產前篩檢尤其明顯，傳統方法導致檢測速度緩慢且介入困難。

此外，政策轉變和監管部門的核准正在增強市場信心，為進一步創新和商業性應用創造有利環境。政府和私人醫療保健組織正在增加對研發計劃的投資，以突破cfDNA檢測在降低疾病發生率和死亡率方面所能取得的成果。隨著分析平台的改進和臨床檢驗研究的增加，cfDNA 檢測正在成為精準醫療的基礎技術。對於相關人員來說，要駕馭這個不斷變化的環境，必須評估影響這個市場未來的機會和挑戰。

針對性檢查的關鍵細分見解

對市場細分的詳細分析揭示了支持cfDNA檢測行業的多面結構。該市場已根據產品範圍進行了廣泛的研究，包括傳染病檢查、腫瘤和癌症管理、產前篩檢和移植檢測。每個領域都解決了重要的診斷需求。在腫瘤學和癌症管理中，重點放在早期檢測和篩檢，以及微量殘存疾病（MRD）評估，以便及時干預和客製化治療方法。同樣，在產前篩檢領域，我們區分非侵入性產前檢查和胚胎著床前基因檢測，為準父母和生育專家提供全面的見解。

此外，基於技術平台的評估描繪了一個高度動態的創新生態系統。市場參與者正在利用各種技術方法，從質譜和微流體到核酸技術、聚合酵素鏈鎖反應（PCR）和單分子甲基化。技術應用的多樣性凸顯了我們致力於提高分析精度和業務效率的決心。

此外，基於最終用戶的細分突顯了診斷實驗室和檢測中心與醫院和診所的不同需求。每個最終用戶群體都需要根據其營運規模和臨床專業化量身定做的解決方案，從而推動對可自訂和整合的測試通訊協定的需求。了解這些細分的細微差別是發現成長機會和設計符合不同臨床和業務相關人員不斷變化的需求的策略的關鍵。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 提高消費者和醫生對非侵入性檢測益處的認知
      • 為了更安全、更早發現胎兒異常，對非侵入性產前檢測的需求日益成長
      • 擴大基因組技術的臨床研究
    • 限制因素
      • 定序技術高成本，減少了無細胞 DNA 診斷的機會
    • 機會
      • 政府投資於優先考慮醫療現代化和精準醫療的政策
      • 個人化醫療策略的日益採用為指導治療計劃提供了重要選擇。
    • 任務
      • 有關敏感遺傳資訊的資料隱私和安全問題
  • 市場區隔分析
    • 提供者：透過使用傳染病檢查支援快速檢測和管理
    • 最終用戶：診斷實驗室因專注於高通量操作而受到青睞
  • 波特五力分析
  • PESTEL 分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第 6 章 無細胞 DNA 檢測市場（以產品提供）

  • 傳染病檢查
  • 腫瘤學和癌症管理
    • 早期檢測和篩檢
    • 微量殘存疾病(MRD) 評估
  • 產前篩檢
    • 非侵入性產前檢測
    • 胚胎著床前基因檢測
  • 移植測試

7. 依技術平台分類的無細胞 DNA 檢測市場

  • 質譜分析
  • 微流體
  • 核酸技術
  • 聚合酵素鏈鎖反應（PCR）
  • 單分子甲基化

第 8 章。

  • 診斷實驗室和檢測中心
  • 醫院和診所

9. 美洲無細胞 DNA 檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10. 亞太地區無細胞 DNA 檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 11 章歐洲、中東和非洲無細胞 DNA 檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Biodesix, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche
  • Fulgent Genetics, Inc.
  • Guardant Health, Inc.
  • Laboratory Corporation of America Holdings
  • llumina, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OPKO Health, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Revvity, Inc
  • SOPHiA GENETICS AG
  • Stilla Technologies
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-4772A7539F05

The Cell-Free DNA Testing Market was valued at USD 6.70 billion in 2024 and is projected to grow to USD 7.19 billion in 2025, with a CAGR of 7.52%, reaching USD 10.36 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 6.70 billion
Estimated Year [2025] USD 7.19 billion
Forecast Year [2030] USD 10.36 billion
CAGR (%) 7.52%

Cell-free DNA (cfDNA) testing has rapidly emerged as a transformative tool within modern diagnostics. This technology, which extracts minute amounts of genetic information from blood or other bodily fluids, not only offers pivotal non-invasive testing options but also paves the way for earlier and more accurate detection of a range of health conditions. In today's healthcare landscape, the ability to capture vital genetic data without the need for surgical interventions has redefined diagnostic practices, fostering a paradigm shift across various clinical workflows.

Recent years have witnessed significant advancements in cfDNA methodologies, leading to its adoption across diverse medical fields including oncology, prenatal care, transplantation monitoring, and infectious disease testing. The growing sophistication of this technology has catalyzed its shift from a niche application to a mainstream diagnostic asset. The integration of high sensitivity platforms and innovative signal detection techniques has not only enhanced the accuracy of these tests but also boosted confidence among healthcare providers and patients alike.

In this comprehensive overview, we explore how cfDNA testing has evolved from its early promise to a current state of maturity, examining key drivers, market segmentations, and leading regional trends. This deep dive aims to equip industry leaders and decision-makers with the insights required to harness this technology in an environment characterized by rapid innovation and heightened clinical expectations.

Transformative Shifts in the Cell-Free DNA Testing Landscape

The landscape of cfDNA testing is undergoing transformative shifts driven by rapid technological advancements and evolving clinical demand. Over the past few years, significant innovations in analytical techniques and assay designs have reshaped the market's architecture. Enhanced sensitivity and specificity, enabled by the integration of next-generation sequencing, microfluidics, and single-molecule methylation analysis, are changing the way clinicians approach early diagnosis and personalized treatment plans.

Historically, invasive biopsy procedures dominated clinical diagnostics, often accompanied by inherent risks and limitations. The shift towards non-invasive cfDNA testing has not only minimized these risks but has also expanded access to critical diagnostic information at earlier stages of disease progression. This evolution is particularly notable in oncology and prenatal screening, where traditional methods have long struggled with late detection and intervention challenges.

Additionally, policy shifts and regulatory approvals have bolstered market confidence, creating an environment conducive to further innovations and commercial adoption. Government and private healthcare entities are increasingly investing in research and development projects to push the boundaries of what cfDNA testing can achieve in reducing disease morbidity and mortality. The convergence of improved analytical platforms and a growing body of clinical validation studies is establishing cfDNA testing as a cornerstone technology in precision medicine. As stakeholders navigate this changing milieu, it becomes imperative to assess both the opportunities and challenges that are shaping this market's future.

Key Segmentation Insights for Targeted and Precision Testing

A granular analysis of market segmentation reveals a multifaceted structure underpinning the cfDNA testing industry. The market is extensively studied based on offerings, which include infectious diseases testing, oncology and cancer management, prenatal screening, and transplantation testing. Each of these areas addresses critical diagnostics needs. In oncology and cancer management, the focus extends further to early detection and screening as well as minimal residual disease (MRD) assessment, allowing for timely intervention and tailored treatment regimens. Similarly, the prenatal screening segment differentiates between non-invasive prenatal testing and preimplantation genetic testing, providing comprehensive insights for expectant parents and fertility specialists.

Moreover, an evaluation based on technology platforms paints a picture of a highly dynamic innovation ecosystem. Market players leverage a range of technological approaches, from mass spectrometry and microfluidics to nucleic acid technology, polymerase chain reaction (PCR), and single-molecule methylation. This diversity in technological application underlines the commitment to enhancing analytical precision and operational efficiency.

Furthermore, the segmentation based on end-users highlights the distinct needs of diagnostic laboratories and testing centers in contrast to hospitals and clinics. Each end-user segment demands solutions tailored to its operational scale and clinical expertise, driving the necessity for customizable and integrative testing protocols. Understanding these segmentation nuances is key to identifying growth opportunities and designing strategies that align with the evolving demands of diverse stakeholders on the clinical and operational fronts.

Based on Offerings, market is studied across Infectious Diseases Testing, Oncology & Cancer Management, Prenatal Screening, and Transplantation Testing. The Oncology & Cancer Management is further studied across Early Detection and Screening and Minimal Residual Disease (MRD) Assessment. The Prenatal Screening is further studied across Non-Invasive Prenatal Testing and Preimplantation Genetic Testing.

Based on Technology Platform, market is studied across Mass Spectrometry, Microfluidics, Nucleic Acid Technology, Polymerase chain reaction (PCR), and Single-molecule Methylation.

Based on End-User, market is studied across Diagnostic Laboratories & Testing Centers and Hospitals & Clinics.

Regional Dynamics: Navigating Global Opportunities and Challenges

Globally, the adoption and evolution of cfDNA testing exhibit varied trends across different regions, each characterized by unique healthcare landscapes and regulatory environments. In the Americas, robust investments in healthcare infrastructure combined with an increasing focus on preventive care have accelerated the integration of cfDNA testing into routine clinical practices. Here, the market benefits from high levels of technological adoption and proactive patient engagement, creating an ecosystem where early diagnosis and personalized medicine are becoming the norm.

The Europe, Middle East & Africa region presents a diverse picture. European markets, with their advanced healthcare systems and regulatory frameworks, have been at the forefront of adopting cutting-edge diagnostic technologies. Simultaneously, emerging markets in the Middle East and Africa are increasingly recognizing the potential of cfDNA testing, driven by rising healthcare demands and initiatives aimed at modernizing diagnostic services. Such dynamics are fostering collaborations between public and private sectors, ensuring that the benefits of early and non-invasive testing reach broader populations.

In the Asia-Pacific region, rapid economic growth and expanding healthcare access are fueling significant market expansion. Countries within this region are investing heavily in technology-driven healthcare solutions, including cfDNA testing. This growth is bolstered by favorable governmental policies, increased R&D activities, and strong collaborations with international biotech companies. While regions continue to face distinct challenges related to infrastructure and regulatory clarity, the underlying momentum towards innovation presents ample opportunities for market players aiming to harness the full potential of cfDNA testing.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Players: Market Innovators and Strategic Movers

The competitive landscape in the cfDNA testing market is marked by the presence of several key industry players who are driving innovation and setting new benchmarks. Companies such as Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., and BGI Genomics Co., Ltd. have been instrumental in developing advanced testing protocols and expanding market access through robust distribution networks. Their continuous investment in research and development is a testament to their commitment to advancing cfDNA technologies.

Further, prominent organizations including Biodesix, Inc., Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche are spearheading initiatives that integrate advanced computational analytics with cutting-edge diagnostic tools, bringing enhanced precision to early detection and disease monitoring. Fulgent Genetics, Inc., Guardant Health, Inc., and Laboratory Corporation of America Holdings are also recognized leaders, utilizing their expansive global outreach to deliver reliable non-invasive diagnostic solutions. The market also benefits from the expertise of llumina, Inc., Myriad Genetics, Inc., Natera, Inc., and OPKO Health, Inc., who have all contributed significantly to the evolution of cfDNA testing methodologies.

Additional market momentum is derived from the initiatives of PerkinElmer, Inc., Qiagen N.V., Revvity, Inc, SOPHiA GENETICS AG, Stilla Technologies, and Thermo Fisher Scientific, Inc. These organizations are known for their innovative approaches, especially in integrating advanced technology platforms such as microfluidics and PCR-based systems. The diversified strengths of these companies not only bolster overall market credibility but also stimulate competitive differentiation and continuous improvements in testing efficacy and turnaround times. Their strategic movements reflect a deep understanding of market needs and a proactive approach to overcoming clinical and operational challenges.

The report delves into recent significant developments in the Cell-Free DNA Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agilent Technologies, Inc., BGI Genomics Co., Ltd., Biodesix, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche, Fulgent Genetics, Inc., Guardant Health, Inc., Laboratory Corporation of America Holdings, llumina, Inc., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., PerkinElmer, Inc., Qiagen N.V., Revvity, Inc, SOPHiA GENETICS AG, Stilla Technologies, and Thermo Fisher Scientific, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders stand at the nexus of innovation and market transformation. It is crucial to adopt an integrative strategy that blends technological advancements with insights drawn from comprehensive market segmentation. Leaders should prioritize investment in cutting-edge analytical platforms while embracing cross-sector collaborations, thereby enhancing the accuracy and reliability of cfDNA testing. Strategic partnerships with technology innovators and clinical research institutions can also bridge the gap between emerging diagnostic capabilities and established healthcare practices.

In addition, focusing on personalized diagnostic approaches will not only cater to the specific demands of various patient populations but also secure a competitive edge in a rapidly evolving market. It is advisable to continuously monitor regulatory developments and leverage data-driven insights to optimize test deployment strategies, ensuring adaptable and scalable solutions that meet both current and future market needs.

Conclusion: Synthesis and Future Outlook

The journey of cfDNA testing from an experimental diagnostic tool to a mainstream clinical asset underscores its transformative potential. The convergence of technological innovations, diverse market segmentations, and dynamic regional trends is reshaping diagnostic paradigms across the globe. Insights into specific market segments, technological platforms, and end-user demands illustrate a landscape characterized by both opportunity and complexity.

As the market continues its upward trajectory, stakeholders are encouraged to adopt forward-thinking approaches that integrate advanced analytics, collaborative ventures, and strategic foresight. The future of cfDNA testing is promising, with sustained advancements poised to further enhance the scope of non-invasive diagnostics and contribute to improved clinical outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising consumer and physician awareness regarding non-invasive testing benefits
      • 5.1.1.2. Growing demand for non-invasive prenatal testing to ensure safer and earlier detection of fetal abnormalities
      • 5.1.1.3. Expanding clinical research in genomic technologies
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of sequencing technology reducing accessibility for cell free DNA diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Government investments in healthcare modernization and policies favoring precision medicine
      • 5.1.3.2. Increasing adoption of personalized medicine strategies is creating significant options for guiding treatment planning
    • 5.1.4. Challenges
      • 5.1.4.1. Data privacy and security concerns related to sensitive genetic information
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offerings: Utilization of infectious disease testing for rapid detection and aiding in the management
    • 5.2.2. End-User: Preference for diagnostic laboratories due to their focus on high-throughput operations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell-Free DNA Testing Market, by Offerings

  • 6.1. Introduction
  • 6.2. Infectious Diseases Testing
  • 6.3. Oncology & Cancer Management
    • 6.3.1. Early Detection and Screening
    • 6.3.2. Minimal Residual Disease (MRD) Assessment
  • 6.4. Prenatal Screening
    • 6.4.1. Non-Invasive Prenatal Testing
    • 6.4.2. Preimplantation Genetic Testing
  • 6.5. Transplantation Testing

7. Cell-Free DNA Testing Market, by Technology Platform

  • 7.1. Introduction
  • 7.2. Mass Spectrometry
  • 7.3. Microfluidics
  • 7.4. Nucleic Acid Technology
  • 7.5. Polymerase chain reaction (PCR)
  • 7.6. Single-molecule Methylation

8. Cell-Free DNA Testing Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories & Testing Centers
  • 8.3. Hospitals & Clinics

9. Americas Cell-Free DNA Testing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cell-Free DNA Testing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cell-Free DNA Testing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Aldevron unveils alchemy, a rapid, purified cell-free DNA technology
    • 12.3.2. Natera expands reproductive health testing with strategic acquisition
    • 12.3.3. Natera secures USD 250M to accelerate personalized cfDNA testing
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies Corporation
  • 3. Agilent Technologies, Inc.
  • 4. BGI Genomics Co., Ltd.
  • 5. Biodesix, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. F. Hoffmann-La Roche
  • 8. Fulgent Genetics, Inc.
  • 9. Guardant Health, Inc.
  • 10. Laboratory Corporation of America Holdings
  • 11. llumina, Inc.
  • 12. Myriad Genetics, Inc.
  • 13. Natera, Inc.
  • 14. OPKO Health, Inc.
  • 15. PerkinElmer, Inc.
  • 16. Qiagen N.V.
  • 17. Revvity, Inc
  • 18. SOPHiA GENETICS AG
  • 19. Stilla Technologies
  • 20. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. CELL-FREE DNA TESTING MARKET MULTI-CURRENCY
  • FIGURE 2. CELL-FREE DNA TESTING MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL-FREE DNA TESTING MARKET RESEARCH PROCESS
  • FIGURE 4. CELL-FREE DNA TESTING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. CELL-FREE DNA TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. CELL-FREE DNA TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL-FREE DNA TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL-FREE DNA TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY INFECTIOUS DISEASES TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY EARLY DETECTION AND SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TRANSPLANTATION TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY NUCLEIC ACID TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY SINGLE-MOLECULE METHYLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES & TESTING CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL-FREE DNA TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CELL-FREE DNA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY ONCOLOGY & CANCER MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CELL-FREE DNA TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. CELL-FREE DNA TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 237. CELL-FREE DNA TESTING MARKET, FPNV POSITIONING MATRIX, 2024